George Bakris to Diabetes Mellitus, Type 2
This is a "connection" page, showing publications George Bakris has written about Diabetes Mellitus, Type 2.
Connection Strength
32.909
-
Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone. JAMA Cardiol. 2023 08 01; 8(8):732-741.
Score: 0.470
-
The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: Post hoc analysis of the FIDELITY study. Diabetes Obes Metab. 2023 10; 25(10):2989-2998.
Score: 0.468
-
Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022 12 01; 45(12):3075-3090.
Score: 0.449
-
A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes. Kidney Int. 2023 01; 103(1):196-206.
Score: 0.446
-
The changing trajectory of diabetic kidney disease. Curr Opin Nephrol Hypertens. 2023 01 01; 32(1):98-102.
Score: 0.445
-
Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2022 11; 102(5):974-989.
Score: 0.444
-
Use of SGLT-2 Inhibitors to Treat Chronic Kidney Disease in Primary Care. J Fam Pract. 2022 07; 71(6 Suppl):S88-S93.
Score: 0.436
-
Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease. Postgrad Med. 2023 Apr; 135(3):224-233.
Score: 0.430
-
Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes. Diabetes Obes Metab. 2022 07; 24(7):1197-1205.
Score: 0.430
-
8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S113-S124.
Score: 0.422
-
3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S39-S45.
Score: 0.422
-
Blood and Urine Biomarkers Predicting Worsening Kidney Function in Patients with Type 2 Diabetes Post-Acute Coronary Syndrome: An Analysis from the EXAMINE Trial. Am J Nephrol. 2021; 52(12):969-976.
Score: 0.420
-
Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects. Nat Rev Nephrol. 2022 01; 18(1):56-70.
Score: 0.416
-
Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial. Cardiovasc Diabetol. 2021 09 14; 20(1):187.
Score: 0.413
-
A Non-purine Xanthine Oxidoreductase Inhibitor Reduces Albuminuria in Patients with DKD: A Randomized Controlled Trial. Kidney360. 2021 08 26; 2(8):1240-1250.
Score: 0.407
-
Red cell distribution width in patients with diabetes and myocardial infarction: An analysis from the EXAMINE trial. Diabetes Obes Metab. 2021 07; 23(7):1580-1587.
Score: 0.400
-
Finerenone and Chronic Kidney Disease Outcomes in Type 2 Diabetes. Reply. N Engl J Med. 2021 03 18; 384(11):e42.
Score: 0.399
-
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial. Clin J Am Soc Nephrol. 2020 12 07; 15(12):1705-1714.
Score: 0.390
-
Diastolic Blood Pressure Does Not Influence Cardiovascular Outcomes in Type 2 Diabetes; or Does It? Diabetes Care. 2020 08; 43(8):1684-1686.
Score: 0.382
-
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. Am J Nephrol. 2019; 50(5):333-344.
Score: 0.362
-
Chronic Kidney Disease in Type 2 Diabetes: Optimizing Glucose-Lowering Therapy. J Fam Pract. 2019 10; 68(8):S1-S6.
Score: 0.361
-
Creatinine Bump Following Antihypertensive Therapy. Hypertension. 2018 12; 72(6):1274-1276.
Score: 0.340
-
Blood Pressure Control and Cardiovascular/Renal Outcomes. Endocrinol Metab Clin North Am. 2018 03; 47(1):175-184.
Score: 0.323
-
Results of ACCORDIAN in ACCORD with lower blood pressure begetting lower mortality in patients with diabetes. Diabetes Obes Metab. 2018 06; 20(6):1335-1336.
Score: 0.323
-
SGLT2 Inhibitors and Mechanisms of Hypertension. Curr Cardiol Rep. 2018 01 19; 20(1):1.
Score: 0.321
-
Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Diabetes Mellitus and Chronic Kidney Disease: Turning the Page. Circulation. 2018 01 09; 137(2):130-133.
Score: 0.320
-
Should Restrictions Be Relaxed for Metformin Use in Chronic Kidney Disease? Yes, They Should Be Relaxed! What's the Fuss? Diabetes Care. 2016 Jul; 39(7):1287-91.
Score: 0.288
-
Finerenone for Albuminuria in Patients With Diabetic Nephropathy--Reply. JAMA. 2016 Jan 19; 315(3):306.
Score: 0.279
-
Management of Hypertension in Diabetic Nephropathy: How Low Should We Go? Blood Purif. 2016; 41(1-3):139-43.
Score: 0.279
-
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA. 2015 Sep 01; 314(9):884-94.
Score: 0.272
-
Update on blood pressure goals in diabetes mellitus. Curr Cardiol Rep. 2015 Jun; 17(6):37.
Score: 0.267
-
Hypertension: Impact of blood pressure lowering in type 2 diabetes. Nat Rev Nephrol. 2015 Jun; 11(6):320-1.
Score: 0.264
-
Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes. Diabetes Care. 2015 Mar; 38(3):429-30.
Score: 0.262
-
Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. Am J Nephrol. 2014; 40(6):572-81.
Score: 0.260
-
In search for the 'sweet spot' for blood pressure level in diabetes. Heart. 2014 Sep 15; 100(18):1404-5.
Score: 0.252
-
Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol. 2014; 40(1):64-74.
Score: 0.251
-
Renin inhibition in patients with chronic kidney disease: is it conclusively non-indicated? J Renin Angiotensin Aldosterone Syst. 2014 Mar; 15(1):97-8.
Score: 0.245
-
Microalbuminuria as a risk predictor in diabetes: the continuing saga. Diabetes Care. 2014; 37(3):867-75.
Score: 0.242
-
Metformin nephrotoxicity insights: will they change clinical management? J Diabetes. 2014 Mar; 6(2):111-2.
Score: 0.242
-
Evidence-based triple antihypertensive therapy yields lower mortality in older patients with diabetes mellitus. Hypertension. 2014 Feb; 63(2):220-1.
Score: 0.241
-
Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy. Clin J Am Soc Nephrol. 2013 Oct; 8(10):1694-701.
Score: 0.236
-
Lowering blood pressure limits in patients with type 2 diabetes: is it still warranted? J Diabetes Complications. 2013 Sep-Oct; 27(5):415-6.
Score: 0.231
-
Effects of nebivolol on aortic compliance in patients with diabetes and maximal renin angiotensin system blockade: the EFFORT study. J Clin Hypertens (Greenwich). 2013 Jul; 15(7):473-9.
Score: 0.231
-
Clinical guidelines: blood pressure goals in T2DM: a Latin American perspective. Nat Rev Endocrinol. 2013 Mar; 9(3):138-9.
Score: 0.227
-
Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2013 Feb; 15(2):92-100.
Score: 0.223
-
Pros and cons of aggressive blood pressure lowering in patients with type 2 diabetes. Curr Vasc Pharmacol. 2012 Mar; 10(2):156-61.
Score: 0.213
-
Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus. Mayo Clin Proc. 2011 May; 86(5):444-56.
Score: 0.201
-
Limitations of metformin use in patients with kidney disease: are they warranted? Diabetes Obes Metab. 2010 Dec; 12(12):1079-83.
Score: 0.196
-
National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. Kidney Int. 2010 Oct; 78(8):726-36.
Score: 0.192
-
Lower blood pressure goals in high-risk cardiovascular patients: are they defensible? Cardiol Clin. 2010 Aug; 28(3):447-52.
Score: 0.191
-
Pathogenesis and treatment of microalbuminuria in patients with diabetes: the road ahead. J Clin Hypertens (Greenwich). 2009 Nov; 11(11):636-43.
Score: 0.181
-
Management of hypertension in patients with diabetes: the place of angiotensin-II receptor blockers. Diabetes Obes Metab. 2009 Aug; 11(8):757-69.
Score: 0.177
-
Mechanistic insights into diuretic-induced insulin resistance. Hypertension. 2008 Dec; 52(6):1009-11.
Score: 0.169
-
Risk factor assessment for new onset diabetes: literature review. Diabetes Obes Metab. 2009 Mar; 11(3):177-87.
Score: 0.165
-
New onset diabetes: can it be delayed? J Hum Hypertens. 2008 Aug; 22(8):517-9.
Score: 0.164
-
Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int. 2008 Jun; 73(11):1303-9.
Score: 0.162
-
Trials that matter: the effect of a fixed-dose combination of an Angiotensin-converting enzyme inhibitor and a diuretic on the complications of type 2 diabetes. Ann Intern Med. 2008 Mar 04; 148(5):400-1.
Score: 0.162
-
Should all patients with type 2 diabetes receive initial combination therapy: an assessment of the ADVANCE trial. Pol Arch Med Wewn. 2007 Sep; 117(9):389-90.
Score: 0.156
-
Antihypertensive agents, insulin sensitivity, and new-onset diabetes. Curr Diab Rep. 2007 Jun; 7(3):191-9.
Score: 0.153
-
Validity and reproducibility of HOMA-IR, 1/HOMA-IR, QUICKI and McAuley's indices in patients with hypertension and type II diabetes. J Hum Hypertens. 2007 Sep; 21(9):709-16.
Score: 0.152
-
Metabolic effects of beta-blockers: importance of dissociating newer from conventional agents. J Hypertens. 2007 Jan; 25(1):249-52; author reply 252-3.
Score: 0.149
-
Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens. 2006 Oct; 24(10):2047-55.
Score: 0.146
-
Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int. 2006 Oct; 70(7):1223-33.
Score: 0.145
-
Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. QJM. 2006 Jul; 99(7):431-6.
Score: 0.143
-
Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension. 2005 Dec; 46(6):1309-15.
Score: 0.138
-
Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension. J Hum Hypertens. 2005 Feb; 19(2):139-44.
Score: 0.131
-
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004 Nov 10; 292(18):2227-36.
Score: 0.129
-
Clinical importance of microalbuminuria in diabetes and hypertension. Curr Hypertens Rep. 2004 Oct; 6(5):352-6.
Score: 0.128
-
The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy. J Clin Hypertens (Greenwich). 2004 Aug; 6(8):437-42; quiz 443-4.
Score: 0.126
-
When does new onset diabetes resulting from antihypertensive therapy increase cardiovascular risk. Hypertension. 2004 May; 43(5):941-2.
Score: 0.123
-
Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials. BMJ Open. 2024 Mar 19; 14(3):e076444.
Score: 0.123
-
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis. Ann Intern Med. 2023 12; 176(12):1606-1616.
Score: 0.120
-
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial. Lancet Diabetes Endocrinol. 2023 Dec; 11(12):892-894.
Score: 0.120
-
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria. Circulation. 2024 Feb 06; 149(6):450-462.
Score: 0.120
-
Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: A FIDELITY subgroup analysis. Diabetes Obes Metab. 2024 Jan; 26(1):191-200.
Score: 0.119
-
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2023 08 31; 38(9):2041-2051.
Score: 0.118
-
Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials. Diabetes Obes Metab. 2023 11; 25(11):3327-3336.
Score: 0.118
-
Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med. 2003 Jul 14; 163(13):1555-65.
Score: 0.117
-
Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations. J Am Coll Cardiol. 2023 06 27; 81(25):2377-2387.
Score: 0.117
-
Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials. J Am Heart Assoc. 2023 07 04; 12(13):e028516.
Score: 0.117
-
The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials. Diabetes Obes Metab. 2023 08; 25(8):2151-2162.
Score: 0.116
-
Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. J Clin Hypertens (Greenwich). 2003 May-Jun; 5(3):202-9.
Score: 0.116
-
Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials. Kidney Int. 2023 07; 104(1):181-188.
Score: 0.116
-
Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE). Nephrol Dial Transplant. 2023 03 31; 38(4):894-903.
Score: 0.115
-
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial. Am J Kidney Dis. 2023 07; 82(1):84-96.e1.
Score: 0.114
-
Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline. Diabetes Obes Metab. 2023 06; 25(6):1512-1522.
Score: 0.114
-
Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study. Nephrol Dial Transplant. 2023 02 13; 38(2):372-383.
Score: 0.114
-
Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial. Diabetes Obes Metab. 2023 05; 25(5):1413-1418.
Score: 0.114
-
Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis. Eur Heart J Cardiovasc Pharmacother. 2023 02 02; 9(2):183-191.
Score: 0.114
-
Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens. 2003 Jan; 17(1):7-12.
Score: 0.113
-
Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease. Eur Heart J Cardiovasc Pharmacother. 2022 12 15; 9(1):85-93.
Score: 0.113
-
Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes. J Hypertens. 2023 02 01; 41(2):295-302.
Score: 0.112
-
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis. Diabetes Care. 2022 12 01; 45(12):2991-2998.
Score: 0.112
-
Effect of finerenone on the occurrence of vision-threatening complications in patients with non-proliferative diabetic retinopathy: Pooled analysis of two studies using routine ophthalmological examinations from clinical trial participants (ReFineDR/DeFineDR). Diabetes Obes Metab. 2023 03; 25(3):894-898.
Score: 0.112
-
Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use. Diabetes Obes Metab. 2023 02; 25(2):407-416.
Score: 0.112
-
ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: what's the evidence. J Clin Hypertens (Greenwich). 2002 Nov-Dec; 4(6):420-3.
Score: 0.112
-
Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria. J Am Coll Cardiol. 2022 11 01; 80(18):1721-1731.
Score: 0.112
-
Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes. Hypertension. 2022 12; 79(12):2685-2695.
Score: 0.111
-
Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes. JACC Heart Fail. 2022 11; 10(11):860-870.
Score: 0.111
-
External validation and extension of the TIMI risk score for heart failure in diabetes for patients with recent acute coronary syndrome: An analysis of the EXAMINE trial. Diabetes Obes Metab. 2023 01; 25(1):229-237.
Score: 0.111
-
Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone-Translational Aspects and Clinical Perspectives across Multiple Organ Systems. Int J Mol Sci. 2022 Aug 17; 23(16).
Score: 0.110
-
Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long-Term Response to Atrasentan in Patients With Diabetic Kidney Disease. Clin Pharmacol Ther. 2022 Nov; 112(5):1098-1107.
Score: 0.110
-
Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial. J Am Heart Assoc. 2022 08 16; 11(16):e025045.
Score: 0.110
-
Glucose-lowering treatment patterns in patients with diabetic kidney disease. Am J Manag Care. 2022 08 01; 28(8):e301-e307.
Score: 0.110
-
Editorial Cycles and Continuity of Diabetes Care. Diabetes Care. 2022 07 07; 45(7):1493-1494.
Score: 0.109
-
Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results. Nephrol Dial Transplant. 2022 06 23; 37(7):1261-1269.
Score: 0.109
-
Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney Int. 2022 08; 102(2):248-260.
Score: 0.109
-
Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes. Curr Hypertens Rep. 2002 Jun; 4(3):185-90.
Score: 0.108
-
Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial. J Diabetes Res. 2022; 2022:9998891.
Score: 0.108
-
Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. Nephrol Dial Transplant. 2022 05 25; 37(6):1014-1023.
Score: 0.108
-
Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial. Eur J Heart Fail. 2022 06; 24(6):996-1005.
Score: 0.108
-
Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure. JACC Heart Fail. 2022 07; 10(7):498-507.
Score: 0.108
-
Kidney function assessment and endpoint ascertainment in clinical trials. Eur Heart J. 2022 04 06; 43(14):1379-1400.
Score: 0.107
-
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care. 2022 04 01; 45(4):888-897.
Score: 0.107
-
Generalizability of FIGARO-DKD and FIDELIO-DKD Trial Criteria to the US Population Eligible for Finerenone. J Am Heart Assoc. 2022 04 05; 11(7):e025079.
Score: 0.107
-
Impact of an ACE inhibitor and calcium antagonist on microalbuminuria and lipid subfractions in type 2 diabetes: a randomised, multi-centre pilot study. J Hum Hypertens. 2002 Mar; 16(3):185-91.
Score: 0.107
-
The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial. Diabetes Metab. 2022 07; 48(4):101331.
Score: 0.106
-
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022 Feb 10; 43(6):474-484.
Score: 0.106
-
Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial. Clin J Am Soc Nephrol. 2022 03; 17(3):361-373.
Score: 0.106
-
Novel Renal Autologous Cell Therapy for Type 2 Diabetes Mellitus Chronic Diabetic Kidney Disease: Clinical Trial Design. Am J Nephrol. 2022; 53(1):50-58.
Score: 0.106
-
Type 2 diabetes: RENAAL and IDNT--the emergence of new treatment options. J Clin Hypertens (Greenwich). 2002 Jan-Feb; 4(1):52-7.
Score: 0.105
-
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. Eur Heart J. 2021 12 21; 42(48):4891-4901.
Score: 0.105
-
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER. Circulation. 2022 02 22; 145(8):575-585.
Score: 0.105
-
DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications. 2022 02; 36(2):108101.
Score: 0.105
-
The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Post Hoc Analysis of the SONAR Randomized Trial. Clin J Am Soc Nephrol. 2021 12; 16(12):1824-1832.
Score: 0.105
-
Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial. Circulation. 2022 02 08; 145(6):437-447.
Score: 0.104
-
Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. J Am Soc Nephrol. 2022 01; 33(1):225-237.
Score: 0.104
-
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial. Diabetes Obes Metab. 2022 01; 24(1):125-134.
Score: 0.104
-
Response by Filippatos et al to Letter Regarding Article, "Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes". Circulation. 2021 09 14; 144(11):e202-e203.
Score: 0.103
-
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021 12 09; 385(24):2252-2263.
Score: 0.103
-
Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. J Am Coll Cardiol. 2021 07 13; 78(2):142-152.
Score: 0.101
-
Influence of sex, age and race on coronary and heart failure events in patients with diabetes and post-acute coronary syndrome. Clin Res Cardiol. 2021 Oct; 110(10):1612-1624.
Score: 0.101
-
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial. Diabetes Obes Metab. 2021 07; 23(7):1652-1659.
Score: 0.100
-
Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis. Clin J Am Soc Nephrol. 2021 03 08; 16(3):384-395.
Score: 0.099
-
Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial. Circulation. 2021 05 04; 143(18):1735-1749.
Score: 0.099
-
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021 01 07; 42(2):152-161.
Score: 0.098
-
Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease. Clin Pharmacol Ther. 2021 06; 109(6):1631-1638.
Score: 0.098
-
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. Am Heart J. 2021 03; 233:141-148.
Score: 0.098
-
Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial. Clin J Am Soc Nephrol. 2020 12 31; 16(1):59-69.
Score: 0.098
-
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. Kidney Int. 2021 04; 99(4):999-1009.
Score: 0.098
-
Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial. Diabetes Obes Metab. 2021 02; 23(2):561-568.
Score: 0.098
-
Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. Circulation. 2021 02 09; 143(6):540-552.
Score: 0.098
-
Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney Int. 2021 03; 99(3):750-762.
Score: 0.097
-
Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial. Lancet Diabetes Endocrinol. 2020 11; 8(11):903-914.
Score: 0.097
-
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 Dec 03; 383(23):2219-2229.
Score: 0.097
-
Multi-proteomic approach to predict specific cardiovascular events in patients with diabetes and myocardial infarction: findings from the EXAMINE trial. Clin Res Cardiol. 2021 Jul; 110(7):1006-1019.
Score: 0.096
-
Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus. Am Heart J. 2020 11; 229:40-51.
Score: 0.096
-
Oral antidiabetic agents safe with renal disease? Postgrad Med. 2000 Jun; 107(7):66.
Score: 0.094
-
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. J Am Soc Nephrol. 2020 05; 31(5):1128-1139.
Score: 0.094
-
Antihypertensive therapy and the risk of type 2 diabetes mellitus. N Engl J Med. 2000 Mar 30; 342(13):969-70.
Score: 0.093
-
Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL. Diabetes Obes Metab. 2020 05; 22(5):798-806.
Score: 0.092
-
Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure. Eur J Heart Fail. 2020 04; 22(4):604-617.
Score: 0.092
-
Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial. J Am Heart Assoc. 2020 01 07; 9(1):e012797.
Score: 0.092
-
Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. Diabetes Care. 2020 02; 43(2):446-452.
Score: 0.091
-
Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial. Circulation. 2020 02 04; 141(5):407-410.
Score: 0.091
-
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. Am J Nephrol. 2019; 50(5):345-356.
Score: 0.091
-
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. Circulation. 2019 08 27; 140(9):739-750.
Score: 0.089
-
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 06 13; 380(24):2295-2306.
Score: 0.087
-
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet. 2019 05 11; 393(10184):1937-1947.
Score: 0.087
-
Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial). Am J Cardiol. 2019 02 01; 123(3):382-391.
Score: 0.085
-
Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial. J Am Heart Assoc. 2018 10 16; 7(20):e009114.
Score: 0.084
-
Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function. Circulation. 2018 10 09; 138(15):1537-1550.
Score: 0.084
-
Risks for renal involvement in diabetes. Postgrad Med. 1998 Sep; 104(3):33.
Score: 0.084
-
Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial. J Am Heart Assoc. 2018 05 16; 7(11).
Score: 0.082
-
Baseline characteristics and enrichment results from the SONAR trial. Diabetes Obes Metab. 2018 08; 20(8):1829-1835.
Score: 0.082
-
Diabetic Kidney Disease: A Determinant of Cardiovascular Risk in Type 1 Diabetes. Diabetes Care. 2018 04; 41(4):662-663.
Score: 0.081
-
Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. J Am Coll Cardiol. 2018 03 27; 71(12):1379-1390.
Score: 0.081
-
Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. Diabetes Obes Metab. 2018 06; 20(6):1369-1376.
Score: 0.081
-
Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study. Am J Nephrol. 2018; 47(1):40-47.
Score: 0.080
-
Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes. Clin J Am Soc Nephrol. 2018 03 07; 13(3):398-405.
Score: 0.080
-
High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial. Diabetes Obes Metab. 2018 03; 20(3):654-659.
Score: 0.079
-
Predictors of renal and cardiovascular mortality in patients with non-insulin-dependent diabetes: a brief overview of microalbuminuria and insulin resistance. J Diabetes Complications. 1997 Nov-Dec; 11(6):352-7.
Score: 0.079
-
Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease. Curr Opin Nephrol Hypertens. 2017 09; 26(5):368-374.
Score: 0.078
-
Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension. 1997 Mar; 29(3):744-50.
Score: 0.075
-
Renal mortality associated with non-insulin-dependent diabetes mellitus. J Diabetes Complications. 1997 Mar-Apr; 11(2):104-11.
Score: 0.075
-
Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care). Circulation. 2017 May 16; 135(20):1911-1921.
Score: 0.075
-
Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial. Diabetes Obes Metab. 2017 05; 19(5):664-671.
Score: 0.075
-
Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. Diabetes. 2017 02; 66(2):241-255.
Score: 0.074
-
Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 1996 Nov; 50(5):1641-50.
Score: 0.074
-
Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS. Diabetes Care. 2016 Dec; 39(12):2304-2310.
Score: 0.073
-
Diabetes: Blood pressure goals in T2DM - time for a rethink? Nat Rev Endocrinol. 2016 11; 12(11):629-630.
Score: 0.073
-
Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. Hypertension. 2016 09; 68(3):606-13.
Score: 0.072
-
Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial. Diabetes Care. 2016 Jul; 39(7):1267-73.
Score: 0.072
-
Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes. J Hypertens. 2016 Apr; 34(4):788-97.
Score: 0.071
-
Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy. J Clin Hypertens (Greenwich). 2016 Apr; 18(4):299-307.
Score: 0.071
-
Effects of dihydropyridine calcium antagonists on albuminuria in patients with diabetes. J Clin Pharmacol. 1996 Mar; 36(3):274-9.
Score: 0.070
-
Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial. Am Heart J. 2016 May; 175:18-27.
Score: 0.070
-
Hypertension: SGLT2 inhibitors: not just another glucose-lowering agent. Nat Rev Nephrol. 2016 Mar; 12(3):128-9.
Score: 0.070
-
Angiotensin converting enzyme inhibitors and calcium antagonists alone or combined: does the progression of diabetic renal disease differ? J Hypertens Suppl. 1995 Aug; 13(2):S95-101.
Score: 0.068
-
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015 May 23; 385(9982):2067-76.
Score: 0.066
-
Hypertension in diabetic patients: an update of interventional studies to preserve renal function. J Clin Pharmacol. 1995 Jan; 35(1):73-80.
Score: 0.065
-
Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. J Card Fail. 2014 Dec; 20(12):953-8.
Score: 0.064
-
Diabetic kidney disease: a report from an ADA Consensus Conference. Am J Kidney Dis. 2014 Oct; 64(4):510-33.
Score: 0.064
-
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014 Oct; 16(10):1016-27.
Score: 0.063
-
Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. Am J Nephrol. 2014; 39(6):499-508.
Score: 0.062
-
Microalbuminuria in non-insulin-dependent diabetes mellitus. Implications for renal survival. Arch Intern Med. 1994 Jan 24; 154(2):146-53.
Score: 0.061
-
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013 12 26; 369(26):2492-503.
Score: 0.060
-
Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial. Nephrol Dial Transplant. 2013 Nov; 28(11):2841-50.
Score: 0.060
-
Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013 Oct 03; 369(14):1327-35.
Score: 0.059
-
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013 May; 15(5):463-73.
Score: 0.057
-
Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON). Am J Nephrol. 2013; 37(3):212-22.
Score: 0.057
-
Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney Int. 1992 Apr; 41(4):912-9.
Score: 0.054
-
Single-pill combination of telmisartan/amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: an 8-week randomized, parallel-group, double-blind trial. Clin Ther. 2012 Mar; 34(3):537-51.
Score: 0.053
-
Risk for renal injury in diabetic hypertensive patients. The physiologic basis for blood pressure control. Postgrad Med. 1992 Feb 15; 91(3):77-80, 83-4.
Score: 0.053
-
Risk for renal injury in diabetic hypertensive patients. Pharmacologic approaches. Postgrad Med. 1992 Feb 15; 91(3):87-91, 94-5.
Score: 0.053
-
EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J. 2011 Oct; 162(4):620-626.e1.
Score: 0.052
-
Telmisartan in incipient and overt diabetic renal disease. J Nephrol. 2011 May-Jun; 24(3):263-73.
Score: 0.050
-
Do fibrates truly preserve kidney function? Nat Rev Endocrinol. 2011 Mar; 7(3):130-1.
Score: 0.050
-
Prevention of microalbuminuria in patients with type 2 diabetes: what do we know? J Clin Hypertens (Greenwich). 2010 Jun; 12(6):422-30.
Score: 0.047
-
Glycemic control and cardiovascular disease in chronic kidney disease. Curr Diab Rep. 2009 Jun; 9(3):243-8.
Score: 0.044
-
Effects of thiazolidinediones beyond glycaemic control. Curr Pharm Des. 2009; 15(5):529-36.
Score: 0.043
-
Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients. Diabetes Obes Metab. 2009 Mar; 11(3):234-8.
Score: 0.041
-
Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) study. J Cardiometab Syndr. 2008; 3(4):211-7.
Score: 0.040
-
Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial. J Clin Hypertens (Greenwich). 2007 Nov; 9(11):842-9.
Score: 0.039
-
The ADVANCE trial: further PROGRESS with HOPE. J Hum Hypertens. 2007 Dec; 21(12):911-3.
Score: 0.039
-
Body weight changes with beta-blocker use: results from GEMINI. Am J Med. 2007 Jul; 120(7):610-5.
Score: 0.039
-
beta-blocker use and diabetes symptom score: results from the GEMINI study. Diabetes Obes Metab. 2007 May; 9(3):408-17.
Score: 0.038
-
Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI. Diabet Med. 2007 Jul; 24(7):759-63.
Score: 0.038
-
Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes. Diabetes Care. 2007 Apr; 30(4):995-6.
Score: 0.037
-
Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J Clin Hypertens (Greenwich). 2006 Jul; 8(7):470-80.
Score: 0.036
-
The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care. 2005 Nov; 28(11):2686-90.
Score: 0.034
-
Effect of fixed-dose ACE-inhibitor/calcium channel blocker combination therapy vs. ACE-inhibitor monotherapy on arterial compliance in hypertensive patients with type 2 diabetes. Prev Cardiol. 2005; 8(2):87-92.
Score: 0.032
-
What have we learned from the current trials? Med Clin North Am. 2004 Jan; 88(1):189-207.
Score: 0.030
-
Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PResión Arterial en DIabéticos tipo Dos) study. J Hypertens. 2004 Jan; 22(1):217-22.
Score: 0.030
-
Hypertension and nephropathy. Am J Med. 2003 Dec 08; 115 Suppl 8A:49S-54S.
Score: 0.030
-
How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy? Curr Hypertens Rep. 2003 Oct; 5(5):418-25.
Score: 0.030
-
The evolution of treatment guidelines for diabetic nephropathy. Strategies integrate JNC VI, more recent protocols. Postgrad Med. 2003 May; 113(5):35-40, 43-4, 50.
Score: 0.029
-
Blood pressure, antihypertensive therapy and risk for renal injury in African-Americans. Curr Opin Nephrol Hypertens. 2003 Jan; 12(1):79-84.
Score: 0.028
-
Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients. Am J Hypertens. 1999 Aug; 12(8 Pt 2):80S-85S.
Score: 0.022
-
Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int. 1998 Oct; 54(4):1283-9.
Score: 0.021
-
Therapeutic challenges in the obese diabetic patient with hypertension. Am J Med. 1996 Sep 30; 101(3A):33S-46S.
Score: 0.018
-
Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014 Oct; 37(10):2864-83.
Score: 0.016
-
Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care. 2011 Jun; 34(6):e61-99.
Score: 0.013
-
Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2011 Jun; 57(6):e1-e47.
Score: 0.013
-
Effects of different calcium antagonists on proteinuria associated with diabetes mellitus. Ann Intern Med. 1990 Dec 15; 113(12):987-8.
Score: 0.012
-
Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. Blood Press. 2007; 16(1):13-9.
Score: 0.009
-
The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich). 2005 Oct; 7(10):578-86.
Score: 0.009